Cradle
AI-powered protein engineering platform for faster R&D
About Cradle
Cradle is an advanced AI platform designed for protein engineering teams in biopharma and industrial biotechnology. It leverages machine learning models to generate and optimize protein candidates across multiple properties simultaneously, including binding affinity, stability, expression, and activity. The platform learns from each round of experimental data provided by users, enabling compounding improvements rather than incremental progress. Cradle supports various protein types including antibodies, enzymes, and therapeutic peptides. Users can manage their experimental rounds, explore AI-generated reports, and track progress through an intuitive interface. The platform is trusted by major companies like Novonesis, Pfizer, Novo Nordisk, and Bayer, with case studies showing 2-12x faster development timelines and significant property improvements in single rounds.
Our Review
Cradle represents a sophisticated solution for protein engineering teams looking to accelerate their R&D timelines. The platform's ability to co-optimize multiple protein properties simultaneously addresses a genuine pain point in the industry where trade-offs typically slow development. Real-world case studies demonstrate impressive results, like improving vaccine thermostability by 2.5°C in a single round and achieving 50% success rates for therapeutic peptides. The learning capability that improves with each experimental round is particularly valuable. However, the platform clearly targets enterprise customers with substantial budgets and existing wet lab capabilities—this isn't a tool for individual researchers or small startups. The lack of transparent pricing and the 'Contact sales' approach may be a barrier for some potential users. The interface appears polished and user-friendly based on screenshots, though actual hands-on experience would vary. The backing from major pharmaceutical and biotech companies lends credibility, but also suggests a premium positioning that may limit accessibility.
Pros & Cons
Pros
Cons